secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mural Oncology plc (—)
CIK:        0001971543
Form:       8-K
Filed at:   2024-05-14T23:59:59+00:00
Accession:  0000950170-24-059071
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mural Oncology Q1 2024 net loss $30.9M, cash runway into Q4 2025 reaffirmed
---------------------------------------------------------------------------

- Net loss $30.9M improved from $46.5M Q1 2023; R&D spend $26.9M down 33% YoY.
- Cash, equivalents & marketable securities $231.7M as of March 31, 2024.
- Nemvaleukin alfa registrational trials on track; ARTISTRY-7 interim OS data Q1 2025.
- Less-frequent IV dosing trial for cutaneous melanoma enrolling; preliminary data H1 2025.
- IL-18/IL-12 preclinical data presented at AACR; candidate nominations expected by end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/0000950170-24-059071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971543/000095017024059071/mura-20240514.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-059071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer